--BodyKrul-- - FACEIT level 9, 1,942 ELO

Poland
On FACEIT since 2015 170 matches tracked 80 matches in 30 days
Last updated:

--BodyKrul-- at a glance

Level 9 1,942 ELO best map Nuke (65%)
Level 9

Last 20 matches compared with 2,992 players in this group: K/R, ADR and win rate below average.

RatingCalculated with the HLTV Rating 1.0 formula from kills, deaths and multi-kills per round. 1.00 is an average match.
better than 2%
0.80
SpreadHow much the rating swings from match to match. The smaller, the more consistent. ±0.25 ConsistencyShare of matches with a rating of 0.90 or higher. 45%
K/R
0.59
better than 4% of players
Level 9 avg: 0.73
Last 12 months
ADR
70.1
better than 8% of players
Level 9 avg: 80.2
Last 12 months
Win rate
45%
better than 31% of players
Level 9 avg: 52%
Last 12 months

Facts

59 ELO Next goal That is 2 to 3 wins.
5 W · 4 L Best day +71 ELO · Oct 9, 2026
13 Comebacks last 90 days
6 W · 3 L Overtime in overtime
Mirage Favorite map 46 of 170 matches
Nuke 65% Map pool tip weakest: Anubis 50%
1 knife kill Rare kills last 90 days
19:00-2:00 Playing times On Sundays
On Tuesdays Best time 63% win rate vs. 54%
FormMapsTiming

59 ELO away from level 10. That is 2 to 3 wins. 5:4 on Oct 9, 2026 (+71 ELO, last 90 days). 13 wins after trailing at halftime (last 90 days). 9 matches in overtime, 6 of them won (last 90 days). Most played: Mirage (46 of 170 matches). Strongest map: Nuke (65% win rate, 17 matches). Weakest: Anubis (50%, 32 matches). 1 knife kill (last 90 days). Plays most on Sundays between 19:00 and 2:00 (based on 170 matches). Best results on Tuesdays: 63% win rate vs. 54% overall (32 matches).

About --BodyKrul--

--BodyKrul-- plays CS2 on FACEIT level 9 with 1,942 ELO. The stats cover 170 matches. The strongest map is Nuke with a 65% win rate in 17 matches. Most played: Mirage with 46 matches and a 54% win rate. --BodyKrul-- won 13 matches after trailing at halftime (last 90 days). Last 20 matches: 9 wins, 11 losses, -10 ELO. --BodyKrul-- does best on Tuesdays: 63% win rate in 32 matches.